Cell Therapy Market is Predicted to Observe a Tremendous Growth, With a CAGR of 14.5% From 2021 To 2028: Grand View Research Inc.
The global cell therapy
market
size is expected to reach USD 23.0
billion by 2028, according to a new report by Grand View Research, Inc. The
market is expected to expand at a CAGR
of 14.5% from 2021 to 2028. The
emergence of new technologies to support the development of advanced cellular
therapies has aided in market growth. Companies are leveraging new technologies
not only for the expansion of their product portfolio but also for establishing
out-licensing or co-development agreements with other entities to support their
product development programs.
Cell-based
therapies hold great potential for replacing, repairing, restoring, or
regenerating damaged tissues, and organs. Researchers are making huge
investments in the development of such effective and safe treatments as an
alternative to conventional treatment strategies which can be further attributed
to the market growth. Out of all therapeutic areas, oncology has the highest
number of ongoing clinical trials. T cells, CD34+ and/or CD133+ stem cells,
mesenchymal stem/stromal cells are predominantly employed for clinical
investigation.
The majority of
biopharmaceutical entities have been affected by the COVID-19 pandemic, while
several cellular therapy development companies have witnessed a strongly
negative impact, which can be attributed to complications in logistics as well
as the manufacturing models employed in this industry. In addition, substantial
and stable funding is imperative to ensure successful commercial translation of
cell-based therapeutics, a factor that was negatively affected in 2020, further
affecting the market growth.
A survey
conducted recently among executives of more than 15 European and U.S. cellular
therapy companies indicated that disruption caused by the pandemic was
significant, which demanded market entities to create strategies to sustain
themselves and plan the next wave of innovative therapies.
Key issues faced
by companies operating in the market include on-time delivery of therapies to
patients at required clinical sites. In addition, the administration of these
therapeutics poses several post-pandemic challenges. Hospitals are hesitant in
offering services, owing to concerns over transmission of SARS-CoV-2,
particularly to vulnerable individuals. Moreover, patients have not been able
to visit cellular therapy centers either, owing to the lockdowns and travel bans.
To Request Sample Copy of this report, click the link:
https://www.grandviewresearch.com/industry-analysis/cell-therapy-market/request/rs1
Cell Therapy Market Report
Highlights
- The
research-use segment dominated the market and accounted for the highest
revenue share in 2020 attributed to extensive research activities for
developing effective cell and gene therapies
- Several cells
such as neural, epithelial, bone marrow mononuclear, fibroblasts, corneal,
antigen-presenting, and chondrocytes, are being explored for the
development of novel therapies
- The
clinical-use segment is expected to witness relatively slow growth through
the forecast period owing to the limited number of FDA-approved cellular
therapies
- Moreover,
there is a withdrawal of several commercialized products and less number
of approved products for clinical-use which further affects the growth of
the clinical-use segment
- Based on the
therapeutic area, the malignancies segment accounted for the largest
revenue share in 2020 owing to the rising application of stem cells in
treating various cancers such as acute myeloid leukemia, multiple myeloma,
and non-Hodgkin lymphoma
- The autologous
therapies segment accounted for the largest revenue share in 2020 and it
continues the trend through the forecast period owing to the high survival
rate associated with this transplant type and relatively high adoption
rate
- The allogenic
therapies segment is expected to witness gradual growth through the
forecast period owing to the high risk of transplant rejection and high
cost associated with allogenic transplants
- North America
has emerged as the highest revenue-generating region in 2020 owing to
extensive investments made by the federal bodies for expanding cellular
therapy research in the region
- In Asia
Pacific, the market is expected to witness a lucrative growth rate owing
to relatively inexpensive manufacturing and operating units, the presence
of a large regional population, and untapped potential
List of Key Players of Cell
Therapy Market
Kolon TissueGene, Inc.;
Anterogen Co., Ltd.; JCR Pharmaceuticals Co., Ltd.; Castle Creek Biosciences,
Inc.; The Future of Biotechnology, MEDIPOST; Osiris Therapeutics, Inc.;
PHARMICELL Co., Ltd.; Tameika Cell Technologies, Inc.; Cells for Cells;
NuVasive, Inc.; Vericel Corporation; Celgene Corporation
Comments
Post a Comment